Navigation Links
Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
Date:3/15/2011

urrent treatments results in high treatment and post-treatment costs to the medical system."

The electroporation technology being sold and licensed to OncoSec is based on Inovio's industry-leading electroporation technology platform that, in addition to DNA vaccines and immune therapeutics, can also be used to efficiently deliver a chemotherapeutic or cytokine agent for the treatment of cancer. When these chemotherapeutic or cytokine agents are injected into a selected treatment area such as a tumor and the predominantly healthy tissue in the margin surrounding a tumor, they have been shown to selectively and quickly destroy the tumor and cancer cells in the tumor margin. The chemotherapeutic agent acts by directly killing cancerous cells at the delivery site. Cytokine agents act by inducing broad, non-antigen specific immune responses that have been shown to kill cancerous cells. These therapies enable heightened concentrations of medicine to be directed to the cancer while reducing overall dosage and moderating or eliminating side effects associated with systemically-applied therapeutic approaches. This optimized delivery is enabled by Inovio's proprietary electroporation process, which locally applies brief controlled electrical pulses to cells to temporarily and reversibly increase permeability of the cell membranes in selected tissue and dramatically increase cellular uptake of the previously injected agent as seen in previous animal studies and earlier human clinical trials.

About OncoSec Medical Inc.OncoSec (OTC BB: ONCS.D), based in San Diego, California, designs, develops and commercializes innovative and proprietary medical approaches to treat solid tumor cancers with unmet medical needs or where currently approved therapies are inadequate based on their efficacy level or side effect profile. The company's therapies are based on the use of electroporation delivery in combination with an approved chemotherapeutic drug or a cytokine agent to
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... PARK, N.C. , Sept. 19, 2014 /PRNewswire/ ... on cloud-based drug design and development, partnering is ... company,s mission is to design new drugs and ... and 2 partners to further their development. The ... portfolio investments. To support this business model, Cloud ...
(Date:9/19/2014)... , Sept. 19, 2014 Research and ... Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market ... For the purposes of this report, the human microbiome ... The human microbiome market is expected to be valued ... at a CAGR of 22.3% within the forecast period of ...
(Date:9/19/2014)... Sept. 19, 2014 The American Association for ... Design and Manufacturing has joined the AAHomecare Corporate Partner ... Harvey Diamond have been actively involved in AAHomecare ... it has quickly grown into a major global manufacturer ... Drive allows AAHomecare to increase efforts on behalf of ...
Breaking Medicine Technology:Cloud Pharmaceuticals Announces Partnering Sessions and Presentation Schedule 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3Drive Medical Design & Manufacturing Joins AAHomecare Corporate Partner Program 2
... Mich., March 6 NanoBio(R) Corporation has,received its third ... having successfully met three critical development milestones:,validating the efficacy ... and demonstrating the strength of its influenza vaccine in,ferret ... of Michigan, has received a,total of $30 million over ...
... lower cardiac toxicity drives ... investigator interest, ... MTA: CTIC) announced today that its investigational drug,pixantrone will be ... Charcot Stichting, in Brussels, Belgium, which sponsors a,consortium of centers ...
Cached Medicine Technology:NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 2Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 3Pixantrone to be Studied in Phase I/II Trial for Aggressive Multiple Sclerosis 4
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... 20, 2014 The excitement is building up once ... North Carolina. This year the Surry Arts Council will be ... around the country who are still fans of the Andy Griffith ... sitcom that aired on CBS from 1960 through 1968. The ... American television history. Mount Airy, North Carolina is where the ...
(Date:9/20/2014)... September 20, 2014 Recently, UWDress.com, an ... and women’s special occasion outfits, has launched a special ... company’s prom outfits are popular among worldwide clients. Now, ... wholesale prom dresses on its website. , ... customers from around the world. Great custom made items ...
(Date:9/20/2014)... 2014 QueenBeeTickets.com is ready to offer ... performances. She will visit many cities in North America ... 16th of April. , Click Here to ... at QueenBeeTickets.com. , The star’s fans are not going ... favorite young singer in a live performance. Ariana Grande ...
(Date:9/20/2014)... 20, 2014 The Arizona Advanced ... is celebrating National Manufacturing Day by opening its doors ... processing and additive manufacturing labs will be offered between ... at MCC’s Southern and Dobson campus (1833 W. Southern ... Lot D. , The AzAMI at MCC was established ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Mayberry Days Parade Cars will be Provided by Mount Airy Toyota and Mount Airy Chrysler Dodge Jeep Ram 2Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:National Manufacturing Day Open House at Mesa Community College Oct. 3 2
... , , , GAITHERSBURG, Md., ... Health and Human Services (HHS) has placed an order for an ... against the 2009 H1N1 influenza virus. This brings HHS orders ... total cumulative contract value of approximately $453 million. Previous HHS ...
... and minimally invasive techniques, study finds , MONDAY, Sept. ... is possible using either minimally invasive or traditional open ... for the type of fracture, researchers say. , The ... factors such as fracture type and degree of septal ...
... in times of uncertainty, people would gravitate toward familiar,favorites. But ... shows that stress and upheaval actually lead people to ... can name our favorite ,comfort foods, and believe that we ... stress and upheaval," writes author Stacy Wood (University of South ...
... , , Projects Target ... WASHINGTON, Sept. 21 Secretary of Veterans Affairs Eric K. Shinseki announced ... $1.4 billion as the Department,s share of spending under the American Recovery ... , , "In putting America back to work, we ...
... FRANCISCO, CA ─ SEPTEMBER 21, 2009 ... drug-eluting stents are effective with a low rate of ... 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored ... study, "The Effect of Drug-Eluting Stents on Clinical and ...
... 2009 A new type of sirolimus-eluting stent ... paclitaxel-eluting stent (PES) with greater vessel wall integrity surrounding ... SES over the PES stent for the trial,s primary ... RES-ELUTION I Trial on the safety and effectiveness of ...
Cached Medicine News:Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 2Health News:MedImmune Receives U.S. Government Order for Additional 29 Million Doses of Nasal Spray Vaccine for 2009 H1N1 Influenza 3Health News:Best Option for Fractured Nose Varies by Patient 2Health News:Comfort food fallacy: Upheaval leads to less-familiar choices 2Health News:Secretary Shinseki Announces Progress on $1.4 Billion in Recovery Act Spending 2Health News:Researchers find drug-eluting stents safe, effective for PCI in diabetics 2Health News:New type of sirolimus-eluting stent demonstrates superior results 2Health News:New type of sirolimus-eluting stent demonstrates superior results 3
PremierEdge™ Stab Knives - 15°....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Interchangeable design allows you to select a single handpiece and change tips during the procedure. Universal connector. Disassembles for easy cleaning. Tips can rotate 360 degrees to re-orient port...
Medicine Products: